Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Anticancer Research

• Publication date

  1995-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 7763013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The current status of camptothecin analogues as antitumor agents.

  1993cited by this paper
• A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.

  1992cited by this paper
• Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line.

  1992cited by this paper
• Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells.

  1992cited by this paper
• Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice

  1992cited by this paper
• Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line.

  1992cited by this paper
• Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.

  1991cited by this paper
• Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.

  1991cited by this paper
• Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells.

  1991cited by this paper
• The S-phase cytotoxicity of camptothecin.

  1991cited by this paper
• Contribution of glutathione and glutathione‐dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines

  1991cited by this paper
• An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

  1990cited by this paper
• Nonlinear pharmacokinetics of CPT-11 in rats.

  1990cited by this paper
• Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines.

  1990cited by this paper
• Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.

  1990cited by this paper
• On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex.

  1989cited by this paper
• DNA topoisomerase poisons as antitumor drugs.

  1989cited by this paper
• Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.

  1989cited by this paper
• Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.

  1989cited by this paper
• Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I.

  1989cited by this paper
• Characterization of a newly established, TA‐4‐producing squamous carcinoma cell line derived from metastatic tongue carcinoma

  1989cited by this paper
• Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.

  1988cited by this paper
• Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells.

  1987cited by this paper
• Elevated DNA topoisomerase II activity in nitrogen mustard-resistant human cells.

  1987cited by this paper
• Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

  1985cited by this paper

• Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).

  2015cites this paper
• Polysaccharide nano-vesicular multidrug carriers for synergistic killing of cancer cells.

  2014cites this paper
• Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

  2014cites this paper
• Second-Line Chemotherapy for Platinum- and Taxane-Resistant Epithelial Ovarian Cancer: Pegylated Liposomal Doxorubicin (PLD), Irinotecan, and Combination Therapies at Lower Doses

  2012cites this paper
• Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503.

  2012cites this paper
• A phase II trial of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).

  2010cites this paper
• Phase II Clinical Study of the Combination Chemotherapy Regimen of Irinotecan Plus Oral Etoposide for the Treatment of Recurrent Ovarian Cancer (Tohoku Gynecologic Cancer Unit 101 Group Study)

  2010cites this paper
• Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer

  2009cites this paper
• Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia

  2008cites this paper
• Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines

  2008cites this paper
• Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.

  2007cites this paper
• A review of topoisomerase inhibition in lung cancer

  2006cites this paper
• Irinotecan plus cisplatin combination against metastatic gastric cancer

  2005cites this paper
• Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro.

  2005cites this paper
• A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed‐dose oral etoposide in patients with solid tumors

  2004cites this paper
• Multidrug resistance in solid tumours

  2004cites this paper
• Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy

  2003cites this paper
• Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.

  2003cites this paper
• Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.

  2003cites this paper
• Irinotecan in esophageal cancer.

  2003cites this paper
• The camptothecins.

  2003cites this paper
• Irinotecan, cisplatin, and radiation in esophageal cancer.

  2002cites this paper
• In vivo advantage of combined administration with CPT-11 and 5-fluorouracil in rats.

  2002cites this paper
• Cisplatin and irinotecan in upper gastrointestinal malignancies.

  2001cites this paper
• Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants

  2001cites this paper
• The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma

  2000cites this paper
• Irinotecan in esophageal cancer.

  2000cites this paper
• Ex vivo activity of XR5000 against solid tumors

  2000cites this paper
• Topotecan (Hycamptin) and Topotecan‐Containing Regimens in the Treatment of Hematologic Malignancies

  2000cites this paper
• Topoisomerase-I inhibitors in gynecologic tumors.

  1999cites this paper
• Topoisomerase-I inhibitors in gynaecologic tumours.

  1998cites this paper
• Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro

  1998cites this paper
• Irinotecan in cervical cancer.

  1998cites this paper
• Irinotecan and cisplatin in upper gastrointestinal malignancies.

  1998influential citation
• Topoisomerase I-targeting drugs. New developments in cancer pharmacology

  1998cites this paper
• Topoisomerase I阻害剤, irinotecan臨床研究の現況

  1998cites this paper
• Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.

  1997cites this paper
• Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

  1997cites this paper
• Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.

  1997cites this paper